BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017;377:2167-2179. [PMID: 29171820 DOI: 10.1056/nejmra1609337] [Cited by in Crossref: 369] [Cited by in F6Publishing: 238] [Article Influence: 73.8] [Reference Citation Analysis]
Number Citing Articles
1 Ustun C, DeFor TE, Karadag FK, Don Yun H, Nathan S, Brunstein CG, Blazar BR, Weisdorf DJ, Holtan SG, Amin K. Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Adv 2020;4:2317-24. [PMID: 32453837 DOI: 10.1182/bloodadvances.2020001793] [Reference Citation Analysis]
2 Le Bastard Q, Chevallier P, Montassier E. Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft vs host disease. World J Gastroenterol 2021; 27(45): 7792-7800 [PMID: 34963742 DOI: 10.3748/wjg.v27.i45.7792] [Reference Citation Analysis]
3 Heidrich V, Bruno JS, Knebel FH, de Molla VC, Miranda-Silva W, Asprino PF, Tucunduva L, Rocha V, Novis Y, Arrais-Rodrigues C, Fregnani ER, Camargo AA. Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2021;12:692225. [PMID: 34220852 DOI: 10.3389/fimmu.2021.692225] [Reference Citation Analysis]
4 Wu K, Yuan Y, Yu H, Dai X, Wang S, Sun Z, Wang F, Fei H, Lin Q, Jiang H, Chen T. The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. Blood 2020;136:501-15. [PMID: 32291445 DOI: 10.1182/blood.2019003990] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 34.0] [Reference Citation Analysis]
5 Furukawa M, Wang X, Ohkawara H, Fukatsu M, Alkebsi L, Takahashi H, Harada-Shirado K, Shichishima-Nakamura A, Kimura S, Ogawa K, Ikezoe T. A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD. Blood Adv 2019;3:2128-43. [PMID: 31300420 DOI: 10.1182/bloodadvances.2019000222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Murata M, Terakura S, Wake A, Miyao K, Ikegame K, Uchida N, Kataoka K, Miyamoto T, Onizuka M, Eto T, Doki N, Ota S, Sato M, Hashii Y, Ichinohe T, Fukuda T, Atsuta Y, Okamoto S, Teshima T. Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. Bone Marrow Transplant 2021. [PMID: 33976381 DOI: 10.1038/s41409-021-01304-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Park MJ, Baek JA, Kim SY, Jung KA, Choi JW, Park SH, Kwok SK, Cho ML. Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells. J Transl Med 2020;18:483. [PMID: 33317573 DOI: 10.1186/s12967-020-02657-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Enriquez J, Mims BMD, Trasti S, Furr KL, Grisham MB. Genomic, microbial and environmental standardization in animal experimentation limiting immunological discovery. BMC Immunol 2020;21:50. [PMID: 32878597 DOI: 10.1186/s12865-020-00380-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Toubai T, Fujiwara H, Rossi C, Riwes M, Tamaki H, Zajac C, Liu C, Mathew AV, Byun J, Oravecz-Wilson K, Matsuda I, Sun Y, Peltier D, Wu J, Chen J, Seregin S, Henig I, Kim S, Brabbs S, Pennathur S, Chen G, Reddy P. Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition. Nat Microbiol 2019;4:800-12. [PMID: 30858572 DOI: 10.1038/s41564-019-0373-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
10 Haring E, Zeiser R, Apostolova P. Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease. Front Immunol 2021;12:705342. [PMID: 34249014 DOI: 10.3389/fimmu.2021.705342] [Reference Citation Analysis]
11 Mathew NR, Vinnakota JM, Apostolova P, Erny D, Hamarsheh S, Andrieux G, Kim JS, Hanke K, Goldmann T, Chappell-Maor L, El-Khawanky N, Ihorst G, Schmidt D, Duyster J, Finke J, Blank T, Boerries M, Blazar BR, Jung S, Prinz M, Zeiser R. Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. J Clin Invest 2020;130:1315-29. [PMID: 31846439 DOI: 10.1172/JCI130272] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
12 Li X, Chen T, Gao Q, Zhang W, Xiao Y, Zhu W, Zeng L, Li Z, Yang S, Wang R, Wang X, Feng Y, Zhang X. A panel of 4 biomarkers for the early diagnosis and therapeutic efficacy of aGVHD. JCI Insight 2019;4:130413. [PMID: 31434801 DOI: 10.1172/jci.insight.130413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Wu Y, Tang CA, Mealer C, Bastian D, Hanief Sofi M, Tian L, Schutt S, Choi HJ, Ticer T, Zhang M, Sui X, Huang L, Mellor AL, Hu CA, Yu XZ. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function. Cell Mol Immunol 2021;18:632-43. [PMID: 33500563 DOI: 10.1038/s41423-020-00611-6] [Reference Citation Analysis]
14 Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein UM, Kröger N. Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level. Bone Marrow Transplant 2020;55:2286-93. [PMID: 32447349 DOI: 10.1038/s41409-020-0952-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Matsuoka S, Hashimoto D, Kadowaki M, Ohigashi H, Hayase E, Yokoyama E, Hasegawa Y, Tateno T, Chen X, Aoyama K, Oka H, Onozawa M, Takeda K, Akashi K, Teshima T. Myeloid differentiation factor 88 signaling in donor T cells accelerates graft-versus-host disease. Haematologica 2020;105:226-34. [PMID: 31048358 DOI: 10.3324/haematol.2018.203380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
16 Mhandire K, Saggu K, Buxbaum NP. Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD). Metabolites 2021;11:736. [PMID: 34822394 DOI: 10.3390/metabo11110736] [Reference Citation Analysis]
17 Rousseau A, Fenolland JR, Labetoulle M. [SARS-CoV-2, COVID-19 and the eye: An update on published data]. J Fr Ophtalmol 2020;43:642-52. [PMID: 32631687 DOI: 10.1016/j.jfo.2020.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yu H, Tian Y, Wang Y, Mineishi S, Zhang Y. Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance. Front Immunol. 2019;10:93. [PMID: 30774630 DOI: 10.3389/fimmu.2019.00093] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
19 Wu N, Liu R, Liang S, Gao H, Xu LP, Zhang XH, Liu J, Huang XJ. γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation. Front Immunol 2021;12:687961. [PMID: 34335589 DOI: 10.3389/fimmu.2021.687961] [Reference Citation Analysis]
20 Wang X, Billick M, Monsour D, Liu J. Central nervous system graft-versus-host disease in a 68-year-old man presenting with myoclonus. CMAJ 2019;191:E1078-81. [PMID: 31570546 DOI: 10.1503/cmaj.190216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kim S, Reddy P. Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease. Front Immunol 2020;11:722. [PMID: 32411139 DOI: 10.3389/fimmu.2020.00722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Bujan Rivera J, Kühl R, Zech U, Hendricks A, Luft T, Dreger P, Friedmann-Bette B, Betz TM, Wiskemann J. Impact of Resistance Exercise and Nutritional Endorsement on physical performance in patients with GvHD (IRENE-G study) - design and rational of a randomized controlled trial. BMC Cancer 2022;22:440. [PMID: 35459108 DOI: 10.1186/s12885-022-09497-1] [Reference Citation Analysis]
23 Chen S, Zeiser R. Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:1854. [PMID: 33013836 DOI: 10.3389/fimmu.2020.01854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Li J, Zhang X, Chen Y, Zheng Q, Zhao M, Jiang H, Dominguez Perles R. A Promising Insight: The Potential Influence and Therapeutic Value of the Gut Microbiota in GI GVHD. Oxidative Medicine and Cellular Longevity 2022;2022:1-13. [DOI: 10.1155/2022/2124627] [Reference Citation Analysis]
25 Zeiser R. Biology-driven developments in the therapy of acute graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2018;2018:236-41. [PMID: 30504316 DOI: 10.1182/asheducation-2018.1.236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Shao L, Pan S, Zhang QP, Jamal M, Chen LH, Yin Q, Wu YJ, Xiong J, Xiao RJ, Kwong YL, Zhou FL, Lie AKW. An Essential Role of Innate Lymphoid Cells in the Pathophysiology of Graft-vs.-Host Disease. Front Immunol. 2019;10:1233. [PMID: 31244831 DOI: 10.3389/fimmu.2019.01233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
27 Iamsawat S, Tian L, Daenthanasanmak A, Wu Y, Nguyen HD, Bastian D, Yu XZ. Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse. Blood Adv 2019;3:4187-201. [PMID: 31856270 DOI: 10.1182/bloodadvances.2019000531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Srinagesh HK, Ferrara JLM. MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application. Best Pract Res Clin Haematol 2019;32:101111. [PMID: 31779977 DOI: 10.1016/j.beha.2019.101111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Khuat LT, Dave M, Murphy WJ. The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation. Gut Microbes 2021;13:1966262. [PMID: 34455917 DOI: 10.1080/19490976.2021.1966262] [Reference Citation Analysis]
30 Brown RA, Byersdorfer CA. Metabolic Pathways in Alloreactive T Cells. Front Immunol 2020;11:1517. [PMID: 32793207 DOI: 10.3389/fimmu.2020.01517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Kim T, Choi Y, Lee JH, Park S, Ahn JS, Moon JH, Shin HJ, Lee WS, Kim D, Lee HS. Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. Korean J Intern Med 2020;35:429-37. [PMID: 30616303 DOI: 10.3904/kjim.2018.317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Lia G, Di Vito C, Cerrano M, Brunello L, Calcaterra F, Tapparo M, Giaccone L, Mavilio D, Bruno B. Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications. Front Immunol 2020;11:422. [PMID: 32265915 DOI: 10.3389/fimmu.2020.00422] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
33 Ma L, Yu J, Zhang H, Zhao B, Zhang J, Yang D, Luo F, Wang B, Jin B, Liu J. Effects of Immune Cells on Intestinal Stem Cells: Prospects for Therapeutic Targets. Stem Cell Rev and Rep. [DOI: 10.1007/s12015-022-10347-7] [Reference Citation Analysis]
34 Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood 2020;135:1739-49. [PMID: 32160294 DOI: 10.1182/blood.2020004823] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 32.0] [Reference Citation Analysis]
35 Schroeder MA, Choi J, Staser K, DiPersio JF. The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biol Blood Marrow Transplant 2018;24:1125-34. [PMID: 29289756 DOI: 10.1016/j.bbmt.2017.12.797] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
36 Adom D, Dillon SR, Yang J, Liu H, Ramadan A, Kushekhar K, Hund S, Albright A, Kirksey M, Adeniyan T, Lewis KE, Evans L, Wu R, Levin SD, Mudri S, Yang J, Rickel E, Seaberg M, Henderson K, Gudgeon CJ, Wolfson MF, Swanson RM, Swiderek KM, Peng SL, Hippen KL, Blazar BR, Paczesny S. ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist. Sci Transl Med 2020;12:eaay4799. [PMID: 33028709 DOI: 10.1126/scitranslmed.aay4799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR. The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Transl Psychiatry 2021;11:58. [PMID: 33462203 DOI: 10.1038/s41398-020-01164-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
38 Jiang H, Fu D, Bidgoli A, Paczesny S. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor. Front Immunol 2021;12:761448. [PMID: 34675938 DOI: 10.3389/fimmu.2021.761448] [Reference Citation Analysis]
39 Zhao JY, Liu SN, Xu LP, Zhang XH, Wang Y, Chen YH, Liu KY, Huang XJ, Mo XD. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. Ann Hematol 2021;100:169-80. [PMID: 33159239 DOI: 10.1007/s00277-020-04273-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Latis E, Michonneau D, Leloup C, Varet H, Peffault de Latour R, Bianchi E, Socié G, Rogge L; CRYOSTEM Consortium. Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. Blood Adv 2020;4:3927-42. [PMID: 32818226 DOI: 10.1182/bloodadvances.2019001032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
41 Mastroianni J, Stickel N, Andrlova H, Hanke K, Melchinger W, Duquesne S, Schmidt D, Falk M, Andrieux G, Pfeifer D, Dierbach H, Schmitt-Graeff A, Meiss F, Boerries M, Zeiser R. miR-146a Controls Immune Response in the Melanoma Microenvironment. Cancer Res 2019;79:183-95. [PMID: 30425059 DOI: 10.1158/0008-5472.CAN-18-1397] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 8.5] [Reference Citation Analysis]
42 Hill GR, Betts BC, Tkachev V, Kean LS, Blazar BR. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol 2021;39:19-49. [PMID: 33428454 DOI: 10.1146/annurev-immunol-102119-073227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Penack O, Peczynski C, van der Werf S, Finke J, Ganser A, Schoemans H, Pavlu J, Niittyvuopio R, Schroyens W, Kaynar L, Blau IW, van der Velden W, Sierra J, Cortelezzi A, Wulf G, Turlure P, Rovira M, Ozkurt Z, Pascual-Cascon MJ, Moreira MC, Clausen J, Greinix H, Duarte RF, Basak GW. Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party. Haematologica 2020;105:1977-83. [PMID: 31601686 DOI: 10.3324/haematol.2019.228668] [Reference Citation Analysis]
44 Igarashi K, Hori T, Yamamoto M, Sohma H, Suzuki N, Tsutsumi H, Kawasaki Y, Kokai Y. CCL8 deficiency in the host abrogates early mortality of acute graft-versus-host disease in mice with dysregulated IL-6 expression. Exp Hematol 2021:S0301-472X(21)00429-X. [PMID: 34808257 DOI: 10.1016/j.exphem.2021.11.006] [Reference Citation Analysis]
45 Chen X, Mayne CG. The Role of Micronutrients in Graft-VS.-Host Disease: Immunomodulatory Effects of Vitamins A and D. Front Immunol 2018;9:2853. [PMID: 30574143 DOI: 10.3389/fimmu.2018.02853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zou Y, Chen BJ. T cell metabolism in graft-versus-host disease. Blood Science 2020;2:16-21. [DOI: 10.1097/bs9.0000000000000035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
47 McDaniel Mims B, Grisham MB. Humanizing the mouse immune system to study splanchnic organ inflammation. J Physiol 2018;596:3915-27. [PMID: 29574759 DOI: 10.1113/JP275325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Zama D, Muratore E, Biagi E, Forchielli ML, Rondelli R, Candela M, Prete A, Pession A, Masetti R. Enteral nutrition protects children undergoing allogeneic hematopoietic stem cell transplantation from blood stream infections. Nutr J 2020;19:29. [PMID: 32276595 DOI: 10.1186/s12937-020-00537-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
49 Lia G, Giaccone L, Leone S, Bruno B. Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role? Front Immunol 2021;12:641427. [PMID: 34093530 DOI: 10.3389/fimmu.2021.641427] [Reference Citation Analysis]
50 Abedin S, Hamadani M. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol 2020;12:549-57. [PMID: 33273867 DOI: 10.2147/JEP.S259290] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Delangre E, Liu J, Tolu S, Maouche K, Armanet M, Cattan P, Pommier G, Bailbé D, Movassat J. Underlying mechanisms of glucocorticoid-induced β-cell death and dysfunction: a new role for glycogen synthase kinase 3. Cell Death Dis 2021;12:1136. [PMID: 34876563 DOI: 10.1038/s41419-021-04419-8] [Reference Citation Analysis]
52 Ferrara JLM, Chaudhry MS. GVHD: biology matters. Hematology Am Soc Hematol Educ Program 2018;2018:221-7. [PMID: 30504314 DOI: 10.1182/asheducation-2018.1.221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Bader CS, Jin L, Levy RB. STING and transplantation: can targeting this pathway improve outcomes? Blood 2021;137:1871-8. [PMID: 33619537 DOI: 10.1182/blood.2020008911] [Reference Citation Analysis]
54 Müskens KF, Lindemans CA, Belderbos ME. Hematopoietic Dysfunction during Graft-Versus-Host Disease: A Self-Destructive Process? Cells 2021;10:2051. [PMID: 34440819 DOI: 10.3390/cells10082051] [Reference Citation Analysis]
55 Biliński J, Jasiński M, Basak GW. The Role of Fecal Microbiota Transplantation in the Treatment of Acute Graft-versus-Host Disease. Biomedicines 2022;10:837. [DOI: 10.3390/biomedicines10040837] [Reference Citation Analysis]
56 Patel DA, Mendoza KA, Chen H, Engelhardt BG, Savani BN, Goodman SA, Warner J, Kassim AA, Byrne M, Chinratanalab W, Greer JP, Hunt C, Jagasia M. Similar Outcomes in Early-Failure Steroid-Dependent Compared to Upfront Steroid Refractory Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplant. J Hematol 2021;10:35-9. [PMID: 33643509 DOI: 10.14740/jh761] [Reference Citation Analysis]
57 Gao J, Xu Y, Ma S, Liang Y, Liu C, Shen J, Sun Z, Niu M, Xu K, Pan B. Inhibition of interleukin-1 receptor-associated kinase 1 decreases murine acute GVHD while preserving graft-versus-lymphoma effect. Transplant Cell Ther 2021:S2666-6367(21)01412-3. [PMID: 34896653 DOI: 10.1016/j.jtct.2021.12.001] [Reference Citation Analysis]
58 Wolf D, Bader CS, Barreras H, Copsel S, Pfeiffer BJ, Lightbourn CO, Altman NH, Komanduri KV, Levy RB. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models. JCI Insight 2018;3:121717. [PMID: 30333311 DOI: 10.1172/jci.insight.121717] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
59 Kordelas L, Schwich E, Dittrich R, Horn PA, Beelen DW, Börger V, Giebel B, Rebmann V. Individual Immune-Modulatory Capabilities of MSC-Derived Extracellular Vesicle (EV) Preparations and Recipient-Dependent Responsiveness. Int J Mol Sci 2019;20:E1642. [PMID: 30987036 DOI: 10.3390/ijms20071642] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
60 Hong YQ, Wan B, Li XF. Macrophage regulation of graft-vs-host disease. World J Clin Cases 2020; 8(10): 1793-1805 [PMID: 32518770 DOI: 10.12998/wjcc.v8.i10.1793] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
61 Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, van den Brink M, Dong C, Huang S, Zang X, Allison JP, Zeiser R, Blazar BR. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. JCI Insight 2019;4:127716. [PMID: 31578305 DOI: 10.1172/jci.insight.127716] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Lin D, Hu B, Li P, Zhao Y, Xu Y, Wu D. Roles of the intestinal microbiota and microbial metabolites in acute GVHD. Exp Hematol Oncol 2021;10:49. [PMID: 34706782 DOI: 10.1186/s40164-021-00240-3] [Reference Citation Analysis]
63 Sofi MH, Tian L, Schutt S, Khan I, Choi HJ, Wu Y, Bastian D, Ticer T, Kassir MF, Atilgan FC, Kim J, Sui X, Zivkovic A, Mehrotra S, O'Bryan JP, Stark H, Martin PJ, Ogretmen B, Yu XZ. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia 2022. [PMID: 35513703 DOI: 10.1038/s41375-022-01581-6] [Reference Citation Analysis]
64 Sun X, He Q, Yang J, Wang A, Zhang F, Qiu H, Zhou K, Wang P, Ding X, Yuan X, Li H, Zhang Y, Song X. Preventive and Therapeutic Effects of a Novel JAK Inhibitor SHR0302 in Acute Graft-Versus-Host Disease. Cell Transplant 2021;30:9636897211033778. [PMID: 34269100 DOI: 10.1177/09636897211033778] [Reference Citation Analysis]
65 Chang YJ, Zhao XY, Huang XJ. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Front Immunol 2018;9:3041. [PMID: 30619371 DOI: 10.3389/fimmu.2018.03041] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
66 Schroeder MA, Hari PN, Blithe A, Paranagama D, Bhatt V, DiPersio JF. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. Bone Marrow Transplant 2022. [PMID: 35437311 DOI: 10.1038/s41409-022-01673-y] [Reference Citation Analysis]
67 D'Amico F, Biagi E, Rampelli S, Fiori J, Zama D, Soverini M, Barone M, Leardini D, Muratore E, Prete A, Gotti R, Pession A, Masetti R, Brigidi P, Turroni S, Candela M. Enteral Nutrition in Pediatric Patients Undergoing Hematopoietic SCT Promotes the Recovery of Gut Microbiome Homeostasis. Nutrients 2019;11:E2958. [PMID: 31817158 DOI: 10.3390/nu11122958] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
68 Zitzer NC, Garzon R, Ranganathan P. Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease. Front Immunol 2018;9:2561. [PMID: 30455702 DOI: 10.3389/fimmu.2018.02561] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
69 Smith M, Zakrzewski J, James S, Sadelain M. Posttransplant chimeric antigen receptor therapy. Blood 2018;131:1045-52. [PMID: 29358181 DOI: 10.1182/blood-2017-08-752121] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
70 Srinagesh HK, Levine JE, Ferrara JLM. Biomarkers in acute graft-versus-host disease: new insights. Ther Adv Hematol 2019;10:2040620719891358. [PMID: 31839920 DOI: 10.1177/2040620719891358] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
71 Spadea M, Saglio F, Opramolla A, Rigazio C, Cisarò F, Berger M, Quarello P, Calvo PL, Fagioli F. Non-Invasive Diagnosis of Pediatric Intestinal Graft-Versus-Host Disease: A Case Series. Transplantology 2022;3:115-23. [DOI: 10.3390/transplantology3020012] [Reference Citation Analysis]
72 Zeiser R, Socié G. The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. Blood Adv 2020;4:3789-94. [PMID: 32780849 DOI: 10.1182/bloodadvances.2020002097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
73 Hülsdünker J, Thomas OS, Haring E, Unger S, Gonzalo Núñez N, Tugues S, Gao Z, Duquesne S, Cywes-Bentley C, Oyardi O, Kirschnek S, Schmitt-Graeff A, Pabst O, Koenecke C, Duyster J, Apostolova P, Blaser MJ, Becher B, Pier GB, Häcker G, Zeiser R. Immunization against poly-N-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity. Proc Natl Acad Sci U S A 2019;116:20700-6. [PMID: 31527267 DOI: 10.1073/pnas.1908549116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
74 Zeiser R. Immune modulatory effects of statins. Immunology 2018;154:69-75. [PMID: 29392731 DOI: 10.1111/imm.12902] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 21.0] [Reference Citation Analysis]
75 Assal A, Mapara MY. Janus Kinase Inhibitors and Cell Therapy. Front Immunol 2021;12:740847. [PMID: 34531878 DOI: 10.3389/fimmu.2021.740847] [Reference Citation Analysis]
76 Luft T, Dreger P, Radujkovic A. Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation. Bone Marrow Transplant 2021. [PMID: 34253879 DOI: 10.1038/s41409-021-01390-y] [Reference Citation Analysis]
77 Aizawa K, Peltier D, Matsuki E, Toubai T. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease? Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103405] [Reference Citation Analysis]
78 Lin A, Brown S, Maloy M, Ruiz JD, Devlin S, DeRespiris L, Proli A, Jakubowski AA, Papadopoulos EB, Sauter CS, Tamari R, Castro-Malaspina H, Shaffer B, Barker J, Perales MA, Giralt SA, Gyurkocza B. Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation. Leuk Lymphoma 2022;:1-8. [PMID: 35142567 DOI: 10.1080/10428194.2022.2032036] [Reference Citation Analysis]
79 Snyder KJ, Zitzer NC, Gao Y, Choe HK, Sell NE, Neidemire-Colley L, Ignaci A, Kale C, Devine RD, Abad MG, Pietrzak M, Wang M, Lin H, Zhang YW, Behbehani GK, Jackman JE, Garzon R, Vaddi K, Baiocchi RA, Ranganathan P. PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease. JCI Insight 2020;5:131099. [PMID: 32191634 DOI: 10.1172/jci.insight.131099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
80 Radojcic V, Paz K, Chung J, Du J, Perkey ET, Flynn R, Ivcevic S, Zaiken M, Friedman A, Yan M, Pletneva MA, Sarantopoulos S, Siebel CW, Blazar BR, Maillard I. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice. Blood 2018;132:2188-200. [PMID: 30181175 DOI: 10.1182/blood-2018-03-841155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
81 Rashidi A, DeFor TE, Holtan SG, Blazar BR, Weisdorf DJ, MacMillan ML. Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 2019;25:2297-302. [PMID: 31325587 DOI: 10.1016/j.bbmt.2019.07.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
82 Kiselevskiy M, Vlasenko R, Reshetnikova V, Chikileva I, Shubina I, Osmanov E, Valiev T, Sidorova N, Batmanova N, Stepanyan N, Kirgizov K, Varfolomeeva S. Potential Use of Mesenchymal Multipotent Cells for Hemopoietic Stem Cell Transplantation: Pro and Contra. J Pediatr Hematol Oncol 2021;43:90-4. [PMID: 33560076 DOI: 10.1097/MPH.0000000000002065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Payen M, Nicolis I, Robin M, Michonneau D, Delannoye J, Mayeur C, Kapel N, Berçot B, Butel MJ, Le Goff J, Socié G, Rousseau C. Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. Blood Adv 2020;4:1824-32. [PMID: 32353108 DOI: 10.1182/bloodadvances.2020001531] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
84 Kövy P, Meggyesi N, Varga L, Balassa K, Bors A, Gopcsa L, Paksi M, Bátai Á, Vad E, Sinkó J, Tordai A, Masszi T, Reményi P, Andrikovics H. Investigation of TGFB1 -1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2020;55:215-23. [PMID: 31527815 DOI: 10.1038/s41409-019-0656-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Isberner N, Kraus S, Grigoleit GU, Aghai F, Kurlbaum M, Zimmermann S, Klinker H, Scherf-Clavel O. Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial. Cancer Chemother Pharmacol 2021;88:973-83. [PMID: 34505930 DOI: 10.1007/s00280-021-04351-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Kobe H, Arita M, Maeda T, Nagata O, Niwa T, Tokioka F, Ishida T. Acute Pulmonary Graft-Versus-Host Disease in a Patient with Adult T-cell Leukemia-Lymphoma Diagnosed by a Cryobiopsy. Intern Med 2021;60:2269-73. [PMID: 33583892 DOI: 10.2169/internalmedicine.6358-20] [Reference Citation Analysis]
87 White MG, Morgan RB, Drazer MW, Eng OS. Gastrointestinal Surgical Emergencies in the Neutropenic Immunocompromised Patient. J Gastrointest Surg 2021. [PMID: 34506017 DOI: 10.1007/s11605-021-05116-9] [Reference Citation Analysis]
88 Shen M, Liu X, Qiu Z, Xu L, Zhang X, Wang Y, Yan C, Chen H, Chen Y, Han W, Wang F, Wang J, Liu S, Liu K, Huang X, Mo X. Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft- versus -host disease after haploidentical allogeneic hematopoietic stem cell transplantation. Therapeutic Advances in Hematology 2022;13:204062072110728. [DOI: 10.1177/20406207211072838] [Reference Citation Analysis]
89 Cao H, Sugimura R. Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells. Cancer Treat Res 2022;183:255-74. [PMID: 35551663 DOI: 10.1007/978-3-030-96376-7_9] [Reference Citation Analysis]
90 Story CM, Wang T, Bhatt VR, Battiwalla M, Badawy SM, Kamoun M, Gragert L, Brown V, Baxter-Lowe LA, Marsh SGE, Gadalla SM, Schetelig J, Mytilineos J, Miklos D, Waller EK, Kuxhausen M, Spellman S, Lee S, Paczesny S, Lansford JL, Vincent BG, Riches ML, Armistead PM; Center for International Blood and Marrow Transplant Research Immunobiology Working Committee. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2021;27:591-9. [PMID: 33882342 DOI: 10.1016/j.jtct.2021.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Ren RR, Ma LM, Xie YX, Tian WW, Wang T. Effect of donor lymphocyte infusion from two types of donors on Mixed Chimerism with Secondary Graft Failure after allogeneic haematopoietic stem cell transplantation. Transplant Cell Ther 2021:S2666-6367(21)01450-0. [PMID: 34973501 DOI: 10.1016/j.jtct.2021.12.017] [Reference Citation Analysis]
92 Tvedt THA, Rose-john S, Tsykunova G, Ahmed AB, Gedde-dahl T, Ersvær E, Bruserud Ø. IL-6 Responsiveness of CD4+ and CD8+ T Cells after Allogeneic Stem Cell Transplantation Differs between Patients and Is Associated with Previous Acute Graft versus Host Disease and Pretransplant Antithymocyte Globulin Therapy. JCM 2022;11:2530. [DOI: 10.3390/jcm11092530] [Reference Citation Analysis]
93 McDaniel Mims B, Enriquez J, Pires Dos Santos A, Jones-Hall Y, Dowd S, Furr KL, Grisham MB. Antibiotic administration exacerbates acute graft vs. host disease-induced bone marrow and spleen damage in lymphopenic mice. PLoS One 2021;16:e0254845. [PMID: 34358240 DOI: 10.1371/journal.pone.0254845] [Reference Citation Analysis]
94 Tian Y, Meng L, Wang Y, Li B, Yu H, Zhou Y, Bui T, Abraham C, Li A, Zhang Y, Wang J, Zhao C, Mineishi S, Gallucci S, Porter D, Hexner E, Zheng H, Zhang Y, Hu S, Zhang Y. Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction. J Clin Invest 2021;131:136774. [PMID: 33090973 DOI: 10.1172/JCI136774] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
95 Zhou Y, Cao L, Guo H, Hong Y, Wang M, Wang K, Huang X, Chang Y. Th2 polarization in target organs is involved in the alleviation of pathological damage mediated by transplanting granulocyte colony-stimulating factor-primed donor T cells. Sci China Life Sci 2021;64:1087-96. [PMID: 32880861 DOI: 10.1007/s11427-020-1754-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Nguyen H, Alawieh A, Bastian D, Kuril S, Dai M, Daenthanasanmak A, Zhang M, Iamsawat S, Schutt SD, Wu Y, Sleiman MM, Shetty A, Atkinson C, Sun S, Varela JC, Tomlinson S, Yu XZ. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. Clin Cancer Res 2020;26:3481-90. [PMID: 31919135 DOI: 10.1158/1078-0432.CCR-19-1717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Yáñez L, Sánchez-Escamilla M, Perales MA. CAR T Cell Toxicity: Current Management and Future Directions. Hemasphere 2019;3:e186. [PMID: 31723825 DOI: 10.1097/HS9.0000000000000186] [Cited by in Crossref: 52] [Cited by in F6Publishing: 32] [Article Influence: 17.3] [Reference Citation Analysis]
98 Luo Y, Xu C, Wang B, Niu Q, Su X, Bai Y, Zhu S, Zhao C, Sun Y, Wang J, Liu M, Sun X, Song G, Cui H, Chen X, Huang H, Wang H, Han M, Jiang E, Shi L, Feng X. Single-cell transcriptomic analysis reveals disparate effector differentiation pathways in human Treg compartment. Nat Commun 2021;12:3913. [PMID: 34162888 DOI: 10.1038/s41467-021-24213-6] [Reference Citation Analysis]
99 Wen Q, Zhao HY, Yao WL, Zhang YY, Fu HX, Wang Y, Xu LP, Zhang XH, Kong Y, Huang XJ. Monocyte subsets in bone marrow grafts may contribute to a low incidence of acute graft-vs-host disease for young donors. J Cell Mol Med 2020;24:9204-16. [PMID: 32608128 DOI: 10.1111/jcmm.15557] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Jauhari S, Chao N. Novel Cellular Therapeutic Approaches for the Prevention and Management of Graft-Versus-Host Disease. Curr Stem Cell Rep 2018;4:318-26. [DOI: 10.1007/s40778-018-0146-4] [Reference Citation Analysis]
101 Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wäsch R, Bertz H, Yücel M, Köhler T, Müller-Quernheim J, Marks R, Finke J. Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2021;56:110-20. [PMID: 32591641 DOI: 10.1038/s41409-020-0986-2] [Reference Citation Analysis]
102 Wang X, Lang S, Tian Y, Zhang J, Yan X, Fang Z, Weng J, Lu N, Wu X, Li T, Cao H, Li Z, Huang X. Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy. ACS Cent Sci 2020;6:382-9. [PMID: 32232138 DOI: 10.1021/acscentsci.9b00956] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
103 Hill GR, Koyama M. Cytokines and costimulation in acute graft-versus-host disease. Blood 2020;136:418-28. [PMID: 32526028 DOI: 10.1182/blood.2019000952] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
104 Köhler N, Ruess DA, Kesselring R, Zeiser R. The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation. Front Immunol 2021;12:634435. [PMID: 33746972 DOI: 10.3389/fimmu.2021.634435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
105 Sarmiento M, Jara V, Soto K, Uribe P, Ocqueteau M, Bertin P, Pereira J. A real life use of ruxolitinib in patients with acute and chronic graft versus host disease refractory to corticosteroid treatment in Latin American patients. Hematol Transfus Cell Ther 2021;43:303-8. [PMID: 33023864 DOI: 10.1016/j.htct.2020.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Hippen KL, Aguilar EG, Rhee SY, Bolivar-Wagers S, Blazar BR. Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease. Trends Immunol 2020;41:77-91. [PMID: 31791718 DOI: 10.1016/j.it.2019.11.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
107 Gooptu M, Antin JH. GVHD Prophylaxis 2020. Front Immunol 2021;12:605726. [PMID: 33897681 DOI: 10.3389/fimmu.2021.605726] [Reference Citation Analysis]
108 Mohammadpour H, Sarow JL, MacDonald CR, Chen GL, Qiu J, Sharma UC, Cao X, Herr MM, Hahn TE, Blazar BR, Repasky EA, McCarthy PL. β2-Adrenergic receptor activation on donor cells ameliorates acute GvHD. JCI Insight 2020;5:137788. [PMID: 32437333 DOI: 10.1172/jci.insight.137788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
109 Rasha F, Mims BM, Castro-Piedras I, Barnes BJ, Grisham MB, Rahman RL, Pruitt K. The Versatility of Sirtuin-1 in Endocrinology and Immunology. Front Cell Dev Biol 2020;8:589016. [PMID: 33330467 DOI: 10.3389/fcell.2020.589016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
110 Qi J, Zhang R, Cai C, Wang H, Zhou M, Shen W, Tang Y, Pan T, Wu D, Han Y. HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant. Ann Hematol 2021;100:2351-61. [PMID: 33846855 DOI: 10.1007/s00277-021-04520-0] [Reference Citation Analysis]
111 Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020;19:185-99. [PMID: 31900462 DOI: 10.1038/s41573-019-0051-2] [Cited by in Crossref: 154] [Cited by in F6Publishing: 142] [Article Influence: 77.0] [Reference Citation Analysis]
112 Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, Rovira M, Ciceri F, Griskevicius L, Blaise D, Forcade E, Mistrik M, Mielke S, Bulabois CE, Niittyvuopio R, Deconinck E, Ruggeri A, Sanz J, Spyridonidis A, Savani B, Giebel S, Nagler A, Mohty M. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. J Hematol Oncol 2020;13:87. [PMID: 32620146 DOI: 10.1186/s13045-020-00923-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
113 Zheng J, Taylor B, Dodge J, Stephans A, Zheng SG, Chen Q, Chen X. Radiation and host retinoic acid signaling promote the induction of gut-homing donor T cells after allogeneic hematopoietic stem cell transplantation. Am J Transplant 2020;20:64-74. [PMID: 31207088 DOI: 10.1111/ajt.15501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Wu YY, Lee JSZ, Chen S, Liu D. Sterile Fluid Transfer for Cell Therapy Manufacturing—The Value of Multiple-Use Aseptic Connector. Front Bioeng Biotechnol 2022;9:806677. [DOI: 10.3389/fbioe.2021.806677] [Reference Citation Analysis]
115 Radtke S, Görgens A, da Conceição Castro SV, Kordelas L, Köninger A, Dürig J, Möllmann M, Horn PA, Giebel B. Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG mice. Sci Rep 2019;9:12914. [PMID: 31501490 DOI: 10.1038/s41598-019-49221-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
116 Ab Rahman S, Matic T, Yordanova M, Ariffin H. HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia? Front Pediatr 2022;9:758680. [DOI: 10.3389/fped.2021.758680] [Reference Citation Analysis]
117 Song Q, Nasri U, Zeng D. Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model. Front Immunol 2022;13:844271. [DOI: 10.3389/fimmu.2022.844271] [Reference Citation Analysis]
118 Su X, Wang Q, Guo W, Pei X, Niu Q, Liu M, Liu Y, Chen S, Feng S, He Y, Yang D, Zhang R, Ma Q, Zhai W, Pang A, Wei J, Huang Y, Luo Y, Han M, Feng X, Jiang E. Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation. Cell Mol Immunol 2020;17:483-95. [PMID: 31664223 DOI: 10.1038/s41423-019-0312-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
119 Peltier D, Reddy P. Non-Coding RNA Mediated Regulation of Allogeneic T Cell Responses After Hematopoietic Transplantation. Front Immunol 2018;9:1110. [PMID: 29963039 DOI: 10.3389/fimmu.2018.01110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
120 Song Q, Kong X, Martin PJ, Zeng D. Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans. Front Immunol 2021;12:700857. [PMID: 34539630 DOI: 10.3389/fimmu.2021.700857] [Reference Citation Analysis]
121 Liu Y, Wang X, Yang F, Zheng Y, Ye T, Yang L. Immunomodulatory Role and Therapeutic Potential of Non-Coding RNAs Mediated by Dendritic Cells in Autoimmune and Immune Tolerance-Related Diseases. Front Immunol 2021;12:678918. [PMID: 34394079 DOI: 10.3389/fimmu.2021.678918] [Reference Citation Analysis]
122 Toubai T, Tamaki H, Peltier DC, Rossi C, Oravecz-Wilson K, Liu C, Zajac C, Wu J, Sun Y, Fujiwara H, Henig I, Kim S, Lombard DB, Reddy P. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation. J Immunol 2018;201:3443-55. [PMID: 30389773 DOI: 10.4049/jimmunol.1800148] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
123 Socié G, Kean LS, Zeiser R, Blazar BR. Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. J Clin Invest 2021;131:149296. [PMID: 34101618 DOI: 10.1172/JCI149296] [Reference Citation Analysis]
124 de Witte MA, Janssen A, Nijssen K, Karaiskaki F, Swanenberg L, van Rhenen A, Admiraal R, van der Wagen L, Minnema MC, Petersen E, Raymakers RAP, Westinga K, Straetemans T, Halkes CJM, Boelens JJ, Kuball J. αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. Blood Adv 2021;5:240-9. [PMID: 33570642 DOI: 10.1182/bloodadvances.2020002444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv 2020;4:2308-16. [PMID: 32453836 DOI: 10.1182/bloodadvances.2019001381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
126 Buchele V, Abendroth B, Büttner-Herold M, Vogler T, Rothamer J, Ghimire S, Ullrich E, Holler E, Neurath MF, Hildner K. Targeting Inflammatory T Helper Cells via Retinoic Acid-Related Orphan Receptor Gamma t Is Ineffective to Prevent Allo-Response-Driven Colitis. Front Immunol 2018;9:1138. [PMID: 29910804 DOI: 10.3389/fimmu.2018.01138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
127 Bastian D, Wu Y, Betts BC, Yu XZ. The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease. Front Immunol 2019;10:988. [PMID: 31139181 DOI: 10.3389/fimmu.2019.00988] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
128 Braun LM, Zeiser R. Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease. Hemasphere 2021;5:e581. [PMID: 34095764 DOI: 10.1097/HS9.0000000000000581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Haring E, Uhl FM, Andrieux G, Proietti M, Bulashevska A, Sauer B, Braun LM, de Vega Gomez E, Esser PR, Martin SF, Pfeifer D, Follo M, Schmitt-Graeff A, Buescher J, Duyster J, Grimbacher B, Boerries M, Pearce EL, Zeiser R, Apostolova P. Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect. Haematologica 2021;106:2131-46. [PMID: 32675222 DOI: 10.3324/haematol.2019.242990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
130 Rowan CM, Pike F, Cooke KR, Krance R, Carpenter PA, Duncan C, Jacobsohn DA, Bollard CM, Cruz CRY, Malatpure A, Farag SS, Renbarger J, Liu H, Bakoyannis G, Hanash S, Paczesny S. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups. Blood 2020;135:1428-37. [PMID: 31972009 DOI: 10.1182/blood.2019002334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
131 Huang Y, Zou Y, Jiao Y, Shi P, Nie X, Huang W, Xiong C, Choi M, Huang C, Macintyre AN, Nichols A, Li F, Li C, Maciver NJ, Cardona D, Brennan TV, Li Z, Chao NJ, Rathmell J, Chen BJ. Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect. Front Immunol 2022;13:751296. [DOI: 10.3389/fimmu.2022.751296] [Reference Citation Analysis]
132 Frankiewicz A, Peczynski C, Giebel S, Harrington A, Socié G, Niederwieser D, Scheid C, Bornhäuser M, Kröger N, Elmaagacli A, Afanasyev B, Dreger P, Rössig C, Blaise D, Kratz C, Yakoub-Agha I, Kremens B, Niemeyer CM, Wulf G, Blau I, Penack O, Greinix H, Basak GW. Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT. Front Immunol 2020;11:1537. [PMID: 32793210 DOI: 10.3389/fimmu.2020.01537] [Reference Citation Analysis]
133 Bruserud Ø, Aarstad HH, Tvedt THA. Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer-What Can We Learn from the Hematological Experience? Cancers (Basel) 2020;12:E1966. [PMID: 32707721 DOI: 10.3390/cancers12071966] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
134 Yang J, Peng B, Wang L, Li X, Li F, Jin X, Jia M, Xu L, Dou L, Liu D. Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy. Ann Hematol 2021. [PMID: 34816294 DOI: 10.1007/s00277-021-04727-1] [Reference Citation Analysis]
135 Héritier J, Medinger M, Heim D, Baldomero H, Arranto C, Halter JP, Passweg JR, Kleber M. Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study. Bone Marrow Transplant 2022. [PMID: 35132203 DOI: 10.1038/s41409-022-01598-6] [Reference Citation Analysis]
136 Lim J, Heo J, Ju H, Shin JW, Kim Y, Lee S, Yu HY, Ryu CM, Yun H, Song S, Hong KS, Chung HM, Kim HR, Roe JS, Choi K, Kim IG, Jeong EM, Shin DM. Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway. Sci Adv 2020;6:eaba1334. [PMID: 32490200 DOI: 10.1126/sciadv.aba1334] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
137 Zhao D, Kim YH, Jeong S, Greenson JK, Chaudhry MS, Hoepting M, Anderson ER, van den Brink MR, Peled JU, Gomes AL, Slingerland AE, Donovan MJ, Harris AC, Levine JE, Ozbek U, Hooper LV, Stappenbeck TS, Ver Heul A, Liu TC, Reddy P, Ferrara JL. Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. J Clin Invest 2018;128:4970-9. [PMID: 30106382 DOI: 10.1172/JCI99261] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
138 Thangavelu G, Du J, Paz KG, Loschi M, Zaiken MC, Flynn R, Taylor PA, Kirchmeier AK, Panoskaltsis-Mortari A, Luznik L, MacDonald KP, Hill GR, Maillard I, Munn DH, Serody JS, Murphy WJ, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Dahlberg C, Miller AT, Blazar BR. Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood 2020;135:28-40. [PMID: 31697815 DOI: 10.1182/blood.2019000032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
139 Tian M, Lyu Y, Wang B, Liu C, Yu L, Shi JH, Liu XM, Zhang XG, Guo K, Li Y, Hu LS. Diagnosis and treatment of acute graft-versus-host disease after liver transplantation: Report of six cases. World J Clin Cases 2021; 9(30): 9255-9268 [PMID: 34786412 DOI: 10.12998/wjcc.v9.i30.9255] [Reference Citation Analysis]
140 Andrlová H, van den Brink MRM, Markey KA. An Unconventional View of T Cell Reconstitution After Allogeneic Hematopoietic Cell Transplantation. Front Oncol 2020;10:608923. [PMID: 33680931 DOI: 10.3389/fonc.2020.608923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Sluyter R, Watson D. Use of Humanized Mouse Models to Investigate the Roles of Purinergic Signaling in Inflammation and Immunity. Front Pharmacol 2020;11:596357. [PMID: 33123018 DOI: 10.3389/fphar.2020.596357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Khurana A, Lin Y. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. Curr Treat Options Oncol 2022. [PMID: 35212892 DOI: 10.1007/s11864-021-00920-6] [Reference Citation Analysis]
143 Tourret M, Talvard-Balland N, Lambert M, Ben Youssef G, Chevalier MF, Bohineust A, Yvorra T, Morin F, Azarnoush S, Lantz O, Dalle JH, Caillat-Zucman S. Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. J Immunother Cancer 2021;9:e003123. [PMID: 34615705 DOI: 10.1136/jitc-2021-003123] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Bowerman KL, Varelias A, Lachner N, Kuns RD, Hill GR, Hugenholtz P. Continuous pre- and post-transplant exposure to a disease-associated gut microbiome promotes hyper-acute graft-versus-host disease in wild-type mice. Gut Microbes 2020;11:754-70. [PMID: 31928131 DOI: 10.1080/19490976.2019.1705729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
145 Paczesny S. Biomarkers for posttransplantation outcomes. Blood. 2018;131:2193-2204. [PMID: 29622549 DOI: 10.1182/blood-2018-02-791509] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
146 Reikvam H, Tvedt T, Johansen S, Aase Setran H, Havre R. Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation. Transplantology 2020;1:102-10. [DOI: 10.3390/transplantology1020010] [Reference Citation Analysis]
147 Salit RB. The role of JAK inhibitors in hematopoietic cell transplantation. Bone Marrow Transplant 2022. [PMID: 35388118 DOI: 10.1038/s41409-022-01649-y] [Reference Citation Analysis]
148 Choi HJ, Tang CA, Tian L, Wu Y, Sofi MH, Ticer T, Schutt SD, Hu CA, Yu XZ. XBP-1s Promotes B Cell Pathogenicity in Chronic GVHD by Restraining the Activity of Regulated IRE-1α-Dependent Decay. Front Immunol 2021;12:705484. [PMID: 34659198 DOI: 10.3389/fimmu.2021.705484] [Reference Citation Analysis]
149 Spilleboudt C, De Wilde V, Lewalle P, Cabanne L, Leclerc M, Beckerich F, Bories D, Cardoso S, Soares MP, Vokaer B, Hougardy JM, Flamand V, Racapé J, Abramowicz M, Maury S, Le Moine A. Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease. Front Immunol 2020;11:579151. [PMID: 33537027 DOI: 10.3389/fimmu.2020.579151] [Reference Citation Analysis]
150 Rajan AV, Trieu H, Chu P, Lin J, Kidambi TD. Assessing the yield and safety of endoscopy in acute graft-vs-host disease after hematopoietic stem cell transplant. World J Gastrointest Endosc 2020; 12(10): 341-354 [PMID: 33133371 DOI: 10.4253/wjge.v12.i10.341] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun 2021;12:6436. [PMID: 34750374 DOI: 10.1038/s41467-021-26683-0] [Reference Citation Analysis]
152 Golay H, Jurkovic Mlakar S, Mlakar V, Nava T, Ansari M. The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review. Int J Mol Sci 2019;20:E3889. [PMID: 31404983 DOI: 10.3390/ijms20163889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
153 Fraint E, Ulloa BA, Feliz Norberto M, Potts KS, Bowman TV. Advances in preclinical hematopoietic stem cell models and possible implications for improving therapeutic transplantation. Stem Cells Transl Med 2021;10:337-45. [PMID: 33058566 DOI: 10.1002/sctm.20-0294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
154 Cuthbertson P, Geraghty NJ, Adhikary SR, Bird KM, Fuller SJ, Watson D, Sluyter R. Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease. Int J Mol Sci 2021;22:8343. [PMID: 34361109 DOI: 10.3390/ijms22158343] [Reference Citation Analysis]
155 Mamo T, Hippen KL, MacMillan ML, Brunstein CG, Miller JS, Wagner JE, Blazar BR, McKenna DH. Regulatory T cells: A review of manufacturing and clinical utility. Transfusion 2022. [PMID: 35015309 DOI: 10.1111/trf.16797] [Reference Citation Analysis]
156 Snyder KJ, Choe HK, Gao Y, Sell NE, Braunreiter KM, Zitzer NC, Neidemire-Colley L, Kalyan S, Dorrance AM, Keller A, Mihaylova MM, Singh S, Sehgal L, Bollag G, Ma Y, Powell B, Devine SM, Ranganathan P. Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease. Front Oncol 2021;11:760789. [PMID: 34722316 DOI: 10.3389/fonc.2021.760789] [Reference Citation Analysis]
157 Cassady K, Martin PJ, Zeng D. Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. Front Immunol 2018;9:3061. [PMID: 30622541 DOI: 10.3389/fimmu.2018.03061] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
158 Sabatelli L, Keränen M, Viayna E, Roset M, Lara N, Thunström D, Pfeiffer M, Nicklasson M, Itälä-Remes M. Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study. Support Care Cancer 2022. [PMID: 35235039 DOI: 10.1007/s00520-022-06915-9] [Reference Citation Analysis]
159 Vandenhove B, Canti L, Schoemans H, Beguin Y, Baron F, Graux C, Kerre T, Servais S. How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation. Front Immunol 2020;11:583564. [PMID: 33193397 DOI: 10.3389/fimmu.2020.583564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Introna M, Golay J. Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD? Front Immunol 2020;11:609063. [PMID: 33362797 DOI: 10.3389/fimmu.2020.609063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Van Lier YF, Van den Brink MRM, Hazenberg MD, Markey KA. The post-hematopoietic cell transplantation microbiome: relationships with transplant outcome and potential therapeutic targets. Haematologica 2021;106:2042-53. [PMID: 33882637 DOI: 10.3324/haematol.2020.270835] [Reference Citation Analysis]
162 Wang K, Lv M, Chang YJ, Zhao XY, Zhao XS, Zhang YY, Sun YQ, Wang ZD, Suo P, Zhou Y, Liu D, Zhai SZ, Hong Y, Wang Y, Zhang XH, Xu LP, Liu KY, Huang XJ. Early myeloid-derived suppressor cells (HLA-DR-/lowCD33+CD16-) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. J Hematol Oncol 2019;12:31. [PMID: 30885244 DOI: 10.1186/s13045-019-0710-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
163 Fischer JC, Bscheider M, Göttert S, Thiele Orberg E, Combs SE, Bassermann F, Heidegger S, Haas T, Poeck H. Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cells. Sci Rep 2019;9:14955. [PMID: 31628411 DOI: 10.1038/s41598-019-51431-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
164 Rashidi A, Herman A, Gomes ALC, Peled JU, Jenq RR, Brereton DG, Staley C, Blazar BR, Weisdorf DJ. An alpha-defensin gene single nucleotide polymorphism modulates the gut microbiota and may alter the risk of acute graft-versus-host disease. Br J Haematol 2020;189:926-30. [PMID: 32086815 DOI: 10.1111/bjh.16458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 Copsel S, Wolf D, Kale B, Barreras H, Lightbourn CO, Bader CS, Alperstein W, Altman NH, Komanduri KV, Levy RB. Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model. Biol Blood Marrow Transplant 2018;24:1788-94. [PMID: 29751114 DOI: 10.1016/j.bbmt.2018.04.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
166 Thiagarajan S, Neurath MF, Hildner K. Resolution of acute intestinal graft-versus-host disease. Semin Immunopathol 2019;41:655-64. [PMID: 31673757 DOI: 10.1007/s00281-019-00769-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
167 Mohamed FA, Thangavelu G, Rhee SY, Sage PT, O'Connor RS, Rathmell JC, Blazar BR. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol 2021;12:757836. [PMID: 34712243 DOI: 10.3389/fimmu.2021.757836] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Pegoraro F, Favre C. Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation. Ann Hematol 2021;100:865-78. [PMID: 33547921 DOI: 10.1007/s00277-021-04433-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
169 Wu HW, Zhao YM, Huang H. [Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:869-77. [PMID: 34788930 DOI: 10.3760/cma.j.issn.0253-2727.2021.10.014] [Reference Citation Analysis]
170 Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M, Passlick B, Schumacher A, Lagies S, Frey A, Schmitt-Graeff A, Burger M, Schmittlutz K, Follo M, von Elverfeldt D, Zhu X, Kammerer B, Diederichs S, Duyster J, Manz MG, Niedermann G, Zeiser R. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett 2022;:215697. [PMID: 35487310 DOI: 10.1016/j.canlet.2022.215697] [Reference Citation Analysis]
171 Servais S, Baron F, Lechanteur C, Seidel L, Selleslag D, Maertens J, Baudoux E, Zachee P, Van Gelder M, Noens L, Kerre T, Lewalle P, Schroyens W, Ory A, Beguin Y. Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. Oncotarget 2018;9:20590-604. [PMID: 29755674 DOI: 10.18632/oncotarget.25020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
172 Drexler B, Buser A, Infanti L, Stehle G, Halter J, Holbro A. Extracorporeal Photopheresis in Graft-versus-Host Disease. Transfus Med Hemother 2020;47:214-25. [PMID: 32595426 DOI: 10.1159/000508169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
173 Ghimire S, Ederer KU, Meedt E, Weber D, Matos C, Hiergeist A, Zeman F, Wolff D, Edinger M, Poeck H, Herr W, Gessner A, Holler E, Bülow S. Low Intestinal IL22 Associates With Increased Transplant-Related Mortality After Allogeneic Stem Cell Transplantation. Front Immunol 2022;13:857400. [DOI: 10.3389/fimmu.2022.857400] [Reference Citation Analysis]
174 Song Q, Wang X, Wu X, Kang TH, Qin H, Zhao D, Jenq RR, van den Brink MRM, Riggs AD, Martin PJ, Chen YZ, Zeng D. IL-22-dependent dysbiosis and mononuclear phagocyte depletion contribute to steroid-resistant gut graft-versus-host disease in mice. Nat Commun 2021;12:805. [PMID: 33547295 DOI: 10.1038/s41467-021-21133-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
175 Furukawa Y, Hamano Y, Shirane S, Kinoshita S, Azusawa Y, Ando J, Nakauchi H, Ando M. Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene Editing. Cells 2022;11:269. [DOI: 10.3390/cells11020269] [Reference Citation Analysis]
176 Dertschnig S, Evans P, Santos E Sousa P, Manzo T, Ferrer IR, Stauss HJ, Bennett CL, Chakraverty R. Graft-versus-host disease reduces lymph node display of tissue-restricted self-antigens and promotes autoimmunity. J Clin Invest 2020;130:1896-911. [PMID: 31917684 DOI: 10.1172/JCI133102] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
177 Paczesny S. Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker. Br J Haematol 2021;192:951-67. [PMID: 32039480 DOI: 10.1111/bjh.16497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
178 Sofi MH, Wu Y, Ticer T, Schutt S, Bastian D, Choi HJ, Tian L, Mealer C, Liu C, Westwater C, Armeson KE, Alekseyenko AV, Yu XZ. A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD. JCI Insight 2021;6:136841. [PMID: 33554953 DOI: 10.1172/jci.insight.136841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
179 Górski A, Jończyk-Matysiak E, Międzybrodzki R, Weber-Dąbrowska B, Borysowski J. "Phage Transplantation in Allotransplantation": Possible Treatment in Graft-Versus-Host Disease? Front Immunol 2018;9:941. [PMID: 29755481 DOI: 10.3389/fimmu.2018.00941] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
180 Thangavelu G, Wang C, Loschi M, Saha A, Osborn MJ, Furlan SN, Aoyama K, McDonald-Hyman C, Aguilar EG, Janesick AS, Chandraratna RA, Refaeli Y, Panoskaltsis-Mortari A, MacDonald KP, Hill GR, Zeiser R, Maillard I, Serody JS, Murphy WJ, Munn DH, Blumberg B, Brown C, Kuchroo V, Kean LS, Hippen KL, Noelle RJ, Blazar BR. Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood 2021;137:1090-103. [PMID: 32976550 DOI: 10.1182/blood.2020005628] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Norona J, Apostolova P, Schmidt D, Ihlemann R, Reischmann N, Taylor G, Köhler N, de Heer J, Heeg S, Andrieux G, Siranosian BA, Schmitt-Graeff A, Pfeifer D, Catalano A, Frew IJ, Proietti M, Grimbacher B, Bulashevska A, Bhatt AS, Brummer T, Clauditz T, Zabelina T, Kroeger N, Blazar BR, Boerries M, Ayuk F, Zeiser R. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. Blood 2020;136:1442-55. [PMID: 32542357 DOI: 10.1182/blood.2020005957] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
182 Rosik J, Szostak B, Machaj F, Pawlik A. The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell Transplantation. Int J Mol Sci 2021;22:3081. [PMID: 33802937 DOI: 10.3390/ijms22063081] [Reference Citation Analysis]
183 DeFilipp Z, Burns LJ, Jaglowski SM, Leppin AL, Pavletic S, Waldman B, Weisdorf DJ, Wood WA, Khera N. A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. Biol Blood Marrow Transplant 2020;26:e305-8. [PMID: 32920205 DOI: 10.1016/j.bbmt.2020.08.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Ehx G, Somja J, Warnatz HJ, Ritacco C, Hannon M, Delens L, Fransolet G, Delvenne P, Muller J, Beguin Y, Lehrach H, Belle L, Humblet-Baron S, Baron F. Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice. Front Immunol 2018;9:1943. [PMID: 30214443 DOI: 10.3389/fimmu.2018.01943] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
185 Uribe-Herranz M, Klein-González N, Rodríguez-Lobato LG, Juan M, de Larrea CF. Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure. Int J Mol Sci 2021;22:1026. [PMID: 33498529 DOI: 10.3390/ijms22031026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Le HT, Keslar K, Nguyen QT, Blazar BR, Hamilton BK, Min B. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease. Front Immunol 2020;11:181. [PMID: 32117306 DOI: 10.3389/fimmu.2020.00181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
187 Rowan CM, Paczesny S. Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation. Clin Lab Med 2019;39:61-72. [PMID: 30709509 DOI: 10.1016/j.cll.2018.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
188 Zhang Y. New hope offered to reduce GVHD. Blood 2021;137:1010-1. [PMID: 33630055 DOI: 10.1182/blood.2020009205] [Reference Citation Analysis]
189 Steinbrunn T, Zovko J, Kraus S. JAK-Inhibitoren für die Behandlung hämatoonkologischer Erkrankungen. Aktuelle Rheumatologie 2020;45:559-67. [DOI: 10.1055/a-1285-4125] [Reference Citation Analysis]
190 Song ZY, Ren HY, Dong YJ, Li Y, Yin Y, Sun YH, Wang Q, Xu WL, Liu W, Ou JP, Liang ZY. Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes. Cancer Manag Res 2020;12:12287-300. [PMID: 33311999 DOI: 10.2147/CMAR.S283855] [Reference Citation Analysis]
191 von Stemann JH, Gjærde LK, Haastrup EK, Minculescu L, Brooks PT, Sengeløv H, Hansen MB, Ostrowski SR. Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles. Sci Rep 2021;11:23971. [PMID: 34907183 DOI: 10.1038/s41598-021-01952-6] [Reference Citation Analysis]
192 Vinnakota JM, Zeiser R. Acute Graft-Versus-Host Disease, Infections, Vascular Events and Drug Toxicities Affecting the Central Nervous System. Front Immunol 2021;12:748019. [PMID: 34691059 DOI: 10.3389/fimmu.2021.748019] [Reference Citation Analysis]
193 Guo WW, Su XH, Wang MY, Han MZ, Feng XM, Jiang EL. Regulatory T Cells in GVHD Therapy. Front Immunol 2021;12:697854. [PMID: 34220860 DOI: 10.3389/fimmu.2021.697854] [Reference Citation Analysis]
194 Pan P, Atkinson SN, Taylor B, Zhu H, Zhou D, Flejsierowicz P, Wang LS, Morse M, Liu C, Gunsolus IL, Chen X. Retinoic Acid Signaling Modulates Recipient Gut Barrier Integrity and Microbiota After Allogeneic Hematopoietic Stem Cell Transplantation in Mice. Front Immunol 2021;12:749002. [PMID: 34759928 DOI: 10.3389/fimmu.2021.749002] [Reference Citation Analysis]
195 García-Bernal D, Palomo M, Martínez CM, Millán-Rivero JE, García-Guillén AI, Blanquer M, Díaz-Ricart M, Sackstein R, Carreras E, Moraleda JM. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease. J Cell Mol Med 2020;24:8031-44. [PMID: 32519822 DOI: 10.1111/jcmm.15434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
196 Bertz H. Rehabilitation after Allogeneic Haematopoietic Stem Cell Transplantation: A Special Challenge. Cancers (Basel) 2021;13:6187. [PMID: 34944808 DOI: 10.3390/cancers13246187] [Reference Citation Analysis]
197 Wu Y, Fu J, Wang H, Yu XZ. Donor T-Cell Repertoire Profiling in Recipient Lymphoid and Parenchyma Organs Reveals GVHD Pathogenesis at Clonal Levels After Bone Marrow Transplantation in Mice. Front Immunol 2021;12:778996. [PMID: 34950143 DOI: 10.3389/fimmu.2021.778996] [Reference Citation Analysis]
198 Zhu J, Patel T, Miller JA, Torrice CD, Aggarwal M, Sketch MR, Alexander MD, Armistead PM, Coghill JM, Grgic T, Jamieson KJ, Ptachcinski JR, Riches ML, Serody JS, Schmitz JL, Shaw JR, Shea TC, Suzuki O, Vincent BG, Wood WA, Rao KV, Wiltshire T, Weimer ET, Crona DJ. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. Int J Mol Sci 2020;21:E858. [PMID: 32013193 DOI: 10.3390/ijms21030858] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
199 Warlick ED, DeFor TE, Bejanyan N, Holtan S, MacMillan M, Blazar BR, Dusenbery K, Arora M, Bachanova V, Cooley S, Lazaryan A, McGlave P, Miller JS, Rashidi A, Slungaard A, Vercellotti G, Ustun C, Brunsein C, Weisdorf D. Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. Biol Blood Marrow Transplant 2019;25:56-62. [PMID: 30077015 DOI: 10.1016/j.bbmt.2018.07.038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
200 Bäuerlein CA, Qureischi M, Mokhtari Z, Tabares P, Brede C, Jordán Garrote AL, Riedel SS, Chopra M, Reu S, Mottok A, Arellano-Viera E, Graf C, Kurzwart M, Schmiedgen K, Einsele H, Wölfl M, Schlegel PG, Beilhack A. A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease. Front Immunol 2020;11:593321. [PMID: 33584657 DOI: 10.3389/fimmu.2020.593321] [Reference Citation Analysis]
201 Rao UK, Engelhardt BG. Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2). Clin Hematol Int 2020;2:101-8. [PMID: 34595450 DOI: 10.2991/chi.d.200506.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Jardine L, Cytlak U, Gunawan M, Reynolds G, Green K, Wang XN, Pagan S, Paramitha M, Lamb CA, Long AK, Hurst E, Nair S, Jackson GH, Publicover A, Bigley V, Haniffa M, Simpson AJ, Collin M. Donor monocyte-derived macrophages promote human acute graft-versus-host disease. J Clin Invest 2020;130:4574-86. [PMID: 32453711 DOI: 10.1172/JCI133909] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
203 Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, Masereeuw R, Netea MG, Levine JE, Morales G, Ferrara JL, Blijlevens NMA, van Oosterhout YVJM, Stelljes M, van der Velden WJFM. Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 2019;25:712-9. [PMID: 30399420 DOI: 10.1016/j.bbmt.2018.10.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
204 Copsel SN, Lightbourn CO, Barreras H, Lohse I, Wolf D, Bader CS, Manov J, Kale BJ, Shah D, Brothers SP, Perez VL, Komanduri KV, Wahlestedt C, Levy RB. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. Front Immunol 2018;9:3104. [PMID: 30733722 DOI: 10.3389/fimmu.2018.03104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
205 MacMillan ML, DeFor TE, Holtan SG, Rashidi A, Blazar BR, Weisdorf DJ. Validation of Minnesota acute graft-versus-host disease Risk Score. Haematologica 2020;105:519-24. [PMID: 31320554 DOI: 10.3324/haematol.2019.220970] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
206 Koyama M, Mukhopadhyay P, Schuster IS, Henden AS, Hülsdünker J, Varelias A, Vetizou M, Kuns RD, Robb RJ, Zhang P, Blazar BR, Thomas R, Begun J, Waddell N, Trinchieri G, Zeiser R, Clouston AD, Degli-Esposti MA, Hill GR. MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. Immunity 2019;51:885-898.e7. [PMID: 31542340 DOI: 10.1016/j.immuni.2019.08.011] [Cited by in Crossref: 57] [Cited by in F6Publishing: 65] [Article Influence: 19.0] [Reference Citation Analysis]
207 Robertson K, Couban S, Leddin D, Ahmad I, Connors L. New onset colitis in an adult patient with chronic granulomatous disease treated with hematopoietic stem cell transplantation: a diagnostic dilemma. Allergy Asthma Clin Immunol 2018;14:17. [PMID: 29755533 DOI: 10.1186/s13223-018-0243-z] [Reference Citation Analysis]
208 Shouval R, Geva M, Nagler A, Youngster I. Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease. Clin Hematol Int 2019;1:28-35. [PMID: 34595408 DOI: 10.2991/chi.d.190316.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
209 Alhaj Hussen K, Michonneau D, Biajoux V, Keita S, Dubouchet L, Nelson E, Setterblad N, Le Buanec H, Bouaziz JD, Guimiot F, Socié G, Canque B. CD4+CD8+ T-Lymphocytes in Xenogeneic and Human Graft-versus-Host Disease. Front Immunol 2020;11:579776. [PMID: 33329550 DOI: 10.3389/fimmu.2020.579776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
210 Vaidya T, Menzer C, Ponce DM, Markova A. Inpatient Management of Mucocutaneous GVHD. Curr Dermatol Rep 2019;8:258-78. [PMID: 33312761 DOI: 10.1007/s13671-019-00280-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
211 Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, Hartwell MJ, Hexner EO, Hogan WJ, Karol AB, Kasikis S, Kitko CL, Kowalyk S, Lin JY, Major-Monfried H, Mielke S, Merli P, Morales G, Ordemann R, Pulsipher MA, Qayed M, Reddy P, Reshef R, Rösler W, Sandhu KS, Schechter T, Shah J, Sigel K, Weber D, Wölfl M, Wudhikarn K, Young R, Levine JE, Ferrara JLM. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv 2019;3:4034-42. [PMID: 31816061 DOI: 10.1182/bloodadvances.2019000791] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
212 Mancusi A, Piccinelli S, Velardi A, Pierini A. CD4+FOXP3+ Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation. Front Immunol 2019;10:2901. [PMID: 31921162 DOI: 10.3389/fimmu.2019.02901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
213 Koenecke C, Krueger A. MicroRNA in T-Cell Development and T-Cell Mediated Acute Graft-Versus-Host Disease. Front Immunol 2018;9:992. [PMID: 29867969 DOI: 10.3389/fimmu.2018.00992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
214 Gao MG, Hong Y, Zhao XY, Pan XA, Sun YQ, Kong J, Wang ZD, Wang FR, Wang JZ, Yan CH, Wang Y, Huang XJ, Zhao XS. The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation. Front Immunol 2021;12:720354. [PMID: 34539656 DOI: 10.3389/fimmu.2021.720354] [Reference Citation Analysis]
215 Gergoudis SC, DeFilipp Z, Özbek U, Sandhu KS, Etra AM, Choe HK, Kitko CL, Ayuk F, Aziz M, Baez J, Ben-David K, Bunworasate U, Gandhi I, Hexner EO, Hogan WJ, Holler E, Kasikis S, Kowalyk SM, Lin JY, Merli P, Morales G, Nakamura R, Reshef R, Rösler W, Srinagesh H, Young R, Chen YB, Ferrara JLM, Levine JE. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin. Blood Adv 2020;4:6098-105. [PMID: 33351103 DOI: 10.1182/bloodadvances.2020003336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
216 Castillo Aleman YM, Ventura-Carmenate Y, Al-Amin MT. Quality of extracorporeal photopheresis care: A pioneering experience in the United Arab Emirates. J Healthc Qual Res 2022:S2603-6479(22)00010-0. [PMID: 35339425 DOI: 10.1016/j.jhqr.2022.02.004] [Reference Citation Analysis]
217 Mankarious M, Matthews NC, Snowden JA, Alfred A. Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD). Front Immunol 2020;11:81. [PMID: 32082329 DOI: 10.3389/fimmu.2020.00081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
218 de Kort EA, de Lil HS, Bremmers MEJ, van Groningen LFJ, Blijlevens NMA, Huls G, Brüggemann RJM, van Dorp S, van der Velden WJFM. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation. PLoS One 2019;14:e0213913. [PMID: 30897127 DOI: 10.1371/journal.pone.0213913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
219 Knaus HA, Rottner T, Baumann CK, Cserna J, Mitterbauer M, Schulenburg A, Rabitsch W, Wohlfarth P. Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria. Transplant Cell Ther 2022;28:260.e1-9. [PMID: 35217212 DOI: 10.1016/j.jtct.2022.02.016] [Reference Citation Analysis]
220 Thangavelu G, Blazar BR. Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease. Front Immunol 2019;10:309. [PMID: 30906290 DOI: 10.3389/fimmu.2019.00309] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
221 At A, T GD, Hm R, Es B, Fl J. Calprotectin expressing donor-derived macrophages increase in acute gastrointestinal graft versus host disease. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.01.028] [Reference Citation Analysis]
222 Pasic I, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Mattsson J, Michelis FV. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. Ann Hematol 2020;99:1377-87. [DOI: 10.1007/s00277-020-04033-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Zhao C, Zhang Y, Zheng H. The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations. Front Immunol 2021;12:717540. [PMID: 34305954 DOI: 10.3389/fimmu.2021.717540] [Reference Citation Analysis]
224 Elgaz S, Kuçi Z, Kuçi S, Bönig H, Bader P. Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. Transfus Med Hemother 2019;46:27-34. [PMID: 31244579 DOI: 10.1159/000496809] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
225 Wu H, Shi J, Luo Y, Tan Y, Zhang M, Lai X, Yu J, Liu L, Fu H, Huang H, Zhao Y. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA Netw Open 2021;4:e2034750. [PMID: 33502484 DOI: 10.1001/jamanetworkopen.2020.34750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
226 Abboud R, Choi J, Ruminski P, Schroeder MA, Kim S, Abboud CN, DiPersio JF. Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease. Ther Adv Hematol 2020;11:2040620720914489. [PMID: 32537114 DOI: 10.1177/2040620720914489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
227 Roll W, Schindler P, Masthoff M, Strotmann R, Albring J, Reicherts C, Weckesser M, Noto B, Stelljes M, Schäfers M, Evers G. 18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD). BMC Cancer 2021;21:1015. [PMID: 34507549 DOI: 10.1186/s12885-021-08748-x] [Reference Citation Analysis]
228 Fujiwara H, Seike K, Brooks MD, Mathew AV, Kovalenko I, Pal A, Lee HJ, Peltier D, Kim S, Liu C, Oravecz-Wilson K, Li L, Sun Y, Byun J, Maeda Y, Wicha MS, Saunders TL, Rehemtulla A, Lyssiotis CA, Pennathur S, Reddy P. Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology. Nat Immunol 2021;22:1440-51. [PMID: 34686860 DOI: 10.1038/s41590-021-01048-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Alam IS, Simonetta F, Scheller L, Mayer AT, Murty S, Vermesh O, Nobashi TW, Lohmeyer JK, Hirai T, Baker J, Lau KH, Negrin R, Gambhir SS. Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease. Cancer Res 2020;80:4780-90. [PMID: 32900772 DOI: 10.1158/0008-5472.CAN-20-1149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Bazzoni R, Takam Kamga P, Tanasi I, Krampera M. Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells. Front Cell Dev Biol 2020;8:596079. [PMID: 33240892 DOI: 10.3389/fcell.2020.596079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
231 Chang CC, Hayase E, Jenq RR. The role of microbiota in allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2021;21:1121-31. [PMID: 33412949 DOI: 10.1080/14712598.2021.1872541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Ikegawa S, Matsuoka KI. Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives. Front Immunol 2021;12:713358. [PMID: 34526990 DOI: 10.3389/fimmu.2021.713358] [Reference Citation Analysis]
233 Duarte LRF, Pinho V, Rezende BM, Teixeira MM. Resolution of Inflammation in Acute Graft-Versus-Host-Disease: Advances and Perspectives. Biomolecules 2022;12:75. [DOI: 10.3390/biom12010075] [Reference Citation Analysis]
234 Poe JC, Jia W, Di Paolo JA, Reyes NJ, Kim JY, Su H, Sundy JS, Cardones AR, Perez VL, Chen BJ, Chao NJ, Cardona DM, Saban DR, Sarantopoulos S. SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. JCI Insight 2018;3:122430. [PMID: 30282825 DOI: 10.1172/jci.insight.122430] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
235 Kuzmina LA, Petinati NA, Vasilieva VA, Dovydenko MV, Drokov MY, Davydova YO, Kapranov NM, Sats NV, Chabaeva YA, Kulikov SM, Gaponova TV, Drize NI, Parovichnikova EN, Savchenko VG. [Multipotent mesenchymal stromal cells application for acute graft versus host disease treatment]. Ter Arkh 2020;92:23-30. [PMID: 33346442 DOI: 10.26442/00403660.2020.07.000757] [Reference Citation Analysis]
236 Hülsdünker J, Ottmüller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, Follo M, Al-Ahmad A, Prinz G, Duquesne S, Dierbach H, Kirschnek S, Lämmermann T, Blaser MJ, Fife BT, Blazar BR, Beilhack A, Hill GR, Häcker G, Zeiser R. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood 2018;131:1858-69. [PMID: 29463561 DOI: 10.1182/blood-2017-10-812891] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 11.5] [Reference Citation Analysis]
237 Radujkovic A, Kordelas L, Dai H, Schult D, Majer-Lauterbach J, Beelen D, Müller-Tidow C, Dreger P, Luft T. Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study. EBioMedicine 2019;49:202-12. [PMID: 31680001 DOI: 10.1016/j.ebiom.2019.10.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
238 Iamsawat S, Daenthanasanmak A, Voss JH, Nguyen H, Bastian D, Liu C, Yu XZ. Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease. J Immunol 2018;201:2812-23. [PMID: 30242073 DOI: 10.4049/jimmunol.1800793] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
239 Bézie S, Charreau B, Vimond N, Lasselin J, Gérard N, Nerrière-Daguin V, Bellier-Waast F, Duteille F, Anegon I, Guillonneau C. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice. Blood Adv 2019;3:3522-38. [PMID: 31730699 DOI: 10.1182/bloodadvances.2019000411] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
240 Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv 2018;2:2012-9. [PMID: 30108109 DOI: 10.1182/bloodadvances.2018013060] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 13.0] [Reference Citation Analysis]
241 Ning X, Wang W, Jin H, Fang W. Low-Density Granulocytes in Immune-Mediated Inflammatory Diseases. Journal of Immunology Research 2022;2022:1-11. [DOI: 10.1155/2022/1622160] [Reference Citation Analysis]
242 Lupsa N, Szegedi Á, Gézsi A, Vuncs Z, Masszi T, Mikala G, Reményi P, Deola S, Lakshmanan AP, Terranegra A, Buzás EI, Pós Z. Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement. Biomedicines 2022;10:519. [DOI: 10.3390/biomedicines10030519] [Reference Citation Analysis]
243 Pession A, Zama D, Muratore E, Leardini D, Gori D, Guaraldi F, Prete A, Turroni S, Brigidi P, Masetti R. Fecal Microbiota Transplantation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review. J Pers Med 2021;11:100. [PMID: 33557125 DOI: 10.3390/jpm11020100] [Reference Citation Analysis]
244 Peltier DC, Roberts A, Reddy P. LNCing RNA to immunity. Trends in Immunology 2022. [DOI: 10.1016/j.it.2022.04.002] [Reference Citation Analysis]
245 Braun LM, Zeiser R. Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease. Front Immunol 2021;12:760199. [PMID: 34868001 DOI: 10.3389/fimmu.2021.760199] [Reference Citation Analysis]
246 Morata-Tarifa C, Macías-Sánchez MDM, Gutiérrez-Pizarraya A, Sanchez-Pernaute R. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis. Stem Cell Res Ther 2020;11:64. [PMID: 32070420 DOI: 10.1186/s13287-020-01592-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
247 Grégoire C, Ritacco C, Hannon M, Seidel L, Delens L, Belle L, Dubois S, Vériter S, Lechanteur C, Briquet A, Servais S, Ehx G, Beguin Y, Baron F. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Front Immunol 2019;10:619. [PMID: 31001253 DOI: 10.3389/fimmu.2019.00619] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
248 Gerner RR, Macheiner S, Reider S, Siegmund K, Grabherr F, Mayr L, Texler B, Moser P, Effenberger M, Schwaighofer H, Moschen AR, Kircher B, Oberacher H, Zeiser R, Tilg H, Nachbaur D. Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity. Leukemia 2020;34:1885-97. [PMID: 31974433 DOI: 10.1038/s41375-020-0709-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
249 Watanabe N, Mamonkin M. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There? Cancer J 2021;27:176-81. [PMID: 33750078 DOI: 10.1097/PPO.0000000000000511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, Yang X, Sun J, Li Z, Han WD, Wang W. Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther 2019;4:35. [PMID: 31637014 DOI: 10.1038/s41392-019-0070-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 20.3] [Reference Citation Analysis]
251 Kroeze A, van Hoeven V, Verheij MW, Turksma AW, Weterings N, van Gassen S, Zeerleder SS, Blom B, Voermans C, Hazenberg MD. Presence of innate lymphoid cells in allogeneic hematopoietic grafts correlates with reduced graft-versus-host disease. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2021.10.011] [Reference Citation Analysis]
252 Muscari I, Fierabracci A, Adorisio S, Moretti M, Cannarile L, Thi Minh Hong V, Ayroldi E, Delfino DV. Glucocorticoids and natural killer cells: A suppressive relationship. Biochem Pharmacol 2022;:114930. [PMID: 35149054 DOI: 10.1016/j.bcp.2022.114930] [Reference Citation Analysis]
253 Shahzad M, Chaudhary SG, Basit A, Thellman C, Rodriguez L, Abhyankar SH, McGuirk JP, Mushtaq MU. Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review. Transpl Immunol 2021;70:101520. [PMID: 34952168 DOI: 10.1016/j.trim.2021.101520] [Reference Citation Analysis]
254 Tang S, Chappell GT, Mazzoli A, Tewari M, Choi SW, Wiens J. Predicting Acute Graft-Versus-Host Disease Using Machine Learning and Longitudinal Vital Sign Data From Electronic Health Records. JCO Clin Cancer Inform 2020;4:128-35. [PMID: 32083957 DOI: 10.1200/CCI.19.00105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
255 Akahane K, Watanabe A, Somazu S, Harama D, Shinohara T, Kasai S, Oshiro H, Goi K, Hasuda N, Ozawa C, Sugita K, Inukai T. Successful treatment of intractable gastrointestinal tract graft-vs-host disease with oral beclomethasone dipropionate in pediatric and young adult patients: Case reports. Medicine (Baltimore) 2022;101:e29054. [PMID: 35356922 DOI: 10.1097/MD.0000000000029054] [Reference Citation Analysis]
256 Ferrara JLM, Chaudhry MS. GVHD: biology matters. Blood Adv 2018;2:3411-7. [PMID: 30482771 DOI: 10.1182/bloodadvances.2018020214] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
257 Yang CY. Comparative Analyses of the Conformational Dynamics Between the Soluble and Membrane-Bound Cytokine Receptors. Sci Rep 2020;10:7399. [PMID: 32366846 DOI: 10.1038/s41598-020-64034-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
258 Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR Cell Therapy-More Than a Pipe Dream. Front Immunol 2020;11:618427. [PMID: 33488631 DOI: 10.3389/fimmu.2020.618427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
259 Adom D, Rowan C, Adeniyan T, Yang J, Paczesny S. Biomarkers for Allogeneic HCT Outcomes. Front Immunol 2020;11:673. [PMID: 32373125 DOI: 10.3389/fimmu.2020.00673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
260 Tago Y, Kobayashi C, Ogura M, Wada J, Yamaguchi S, Yamaguchi T, Hayashi M, Nakaishi T, Kubo H, Ueda Y. Human amnion-derived mesenchymal stem cells attenuate xenogeneic graft-versus-host disease by preventing T cell activation and proliferation. Sci Rep 2021;11:2406. [PMID: 33510297 DOI: 10.1038/s41598-021-81916-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
261 Enok Bonong PR, Zahreddine M, Buteau C, Duval M, Laporte L, Lacroix J, Alfieri C, Trottier H. Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2021;9:288. [PMID: 33808928 DOI: 10.3390/vaccines9030288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
262 Gao F, Zhang J, Hu J, Lin L, Xu Y. Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis. Ann Hematol 2021;100:529-40. [PMID: 33420575 DOI: 10.1007/s00277-021-04399-x] [Reference Citation Analysis]
263 Iliopoulou BP, Hsu K, Pérez-Cruz M, Tang SW, Pang WW, Erkers T, Kambham N, Freeman GJ, Dekruyff RH, Meyer EH. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation. Blood Adv 2019;3:3419-31. [PMID: 31714958 DOI: 10.1182/bloodadvances.2019000286] [Reference Citation Analysis]
264 Tews D, Schulz A, Denzer C, von Schnurbein J, Ceccarini G, Debatin KM, Wabitsch M. Lipodystrophy as a Late Effect after Stem Cell Transplantation. J Clin Med 2021;10:1559. [PMID: 33917653 DOI: 10.3390/jcm10081559] [Reference Citation Analysis]
265 Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol 2019;6:e132-43. [PMID: 30824040 DOI: 10.1016/S2352-3026(18)30221-7] [Cited by in Crossref: 88] [Cited by in F6Publishing: 49] [Article Influence: 29.3] [Reference Citation Analysis]
266 Lewis D, Glehn-Ponsirenas R, Gulbahce N, Hooey LJ, Chaffin JM, Miles J, Woodward R, Duarte S, Beduschi T, Zarrinpar A. High levels of donor-derived cell-free DNA in a case of graft-versus-host-disease following liver transplantation. Am J Transplant 2021. [PMID: 34825479 DOI: 10.1111/ajt.16894] [Reference Citation Analysis]
267 Saha A, Hyzy S, Lamothe T, Hammond K, Clark N, Lanieri L, Bhattarai P, Palchaudhuri R, Gillard GO, Proctor J, Riddle MJ, Panoskaltsis-Mortari A, MacMillan ML, Wagner JE, Kiem HP, Olson LM, Blazar BR. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice. Blood 2022;139:1743-59. [PMID: 34986233 DOI: 10.1182/blood.2021012366] [Reference Citation Analysis]
268 Lyu T, Zhang B, Li M, Jiao X, Song Y. Research progress on exosomes derived from mesenchymal stem cells in hematological malignancies. Hematol Oncol 2021;39:162-9. [PMID: 32869900 DOI: 10.1002/hon.2793] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
269 Mashima K, Sato K, Ikeda T, Izawa J, Takayama N, Hayakawa H, Kawaguchi SI, Nakano H, Nagayama T, Umino K, Morita K, Tominaga K, Endo H, Kanda Y. Dimethyl fumarate ameliorates graft-versus-host disease by inhibiting T-cell metabolism and immune responses through a reactive oxygen species-dependent mechanism. Br J Haematol 2022. [PMID: 35170051 DOI: 10.1111/bjh.18082] [Reference Citation Analysis]
270 Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia 2020;34:1229-40. [PMID: 32242050 DOI: 10.1038/s41375-020-0804-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
271 Goldsmith SR, Ghobadi A, DiPersio JF. Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors? Front Oncol 2020;10:608916. [PMID: 33415078 DOI: 10.3389/fonc.2020.608916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
272 Wenzel F, Pralong A, Holtick U, Scheid C, Herling M, Simon ST. Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review. Cancers (Basel) 2021;13:2697. [PMID: 34070773 DOI: 10.3390/cancers13112697] [Reference Citation Analysis]
273 Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation. Nat Rev Cancer 2018;18:283-95. [PMID: 29449660 DOI: 10.1038/nrc.2018.10] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 22.0] [Reference Citation Analysis]
274 Schwarz CS, Bucher CH, Schlundt C, Mertlitz S, Riesner K, Kalupa M, Verlaat L, Schmidt-Bleek O, Sass RA, Schmidt-Bleek K, Duda GN, Penack O, Na IK. Spatio-Temporal Bone Remodeling after Hematopoietic Stem Cell Transplantation. Int J Mol Sci 2020;22:E267. [PMID: 33383915 DOI: 10.3390/ijms22010267] [Reference Citation Analysis]
275 Daenthanasanmak A, Iamsawat S, Chakraborty P, Nguyen HD, Bastian D, Liu C, Mehrotra S, Yu XZ. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice. Blood 2019;133:266-79. [PMID: 30514750 DOI: 10.1182/blood-2018-07-863233] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
276 Murata M, Teshima T. Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease Using Commercial Mesenchymal Stem Cell Products. Front Immunol 2021;12:724380. [PMID: 34489977 DOI: 10.3389/fimmu.2021.724380] [Reference Citation Analysis]
277 Dhakal B, Chhabra S, Savani BN, Hamadani M. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. Br J Haematol 2021. [PMID: 34671973 DOI: 10.1111/bjh.17904] [Reference Citation Analysis]
278 Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant 2019;25:1347-54. [PMID: 30826465 DOI: 10.1016/j.bbmt.2019.02.022] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
279 Yang J, Ramadan A, Reichenbach DK, Loschi M, Zhang J, Griesenauer B, Liu H, Hippen KL, Blazar BR, Paczesny S. Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease. JCI Insight 2019;4:122014. [PMID: 30694220 DOI: 10.1172/jci.insight.122014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
280 Divito SJ, Aasebø AT, Matos TR, Hsieh PC, Collin M, Elco CP, O'Malley JT, Bækkevold ES, Reims H, Gedde-Dahl T, Hagerstrom M, Hilaire J, Lian JW, Milford EL, Pinkus GS, Ho VT, Soiffer RJ, Kim HT, Mihm MC, Ritz J, Guleria I, Cutler CS, Clark RA, Jahnsen FL, Kupper TS. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest 2020;130:4624-36. [PMID: 32516138 DOI: 10.1172/JCI129965] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
281 Ogawa Y, Kawakami Y, Tsubota K. Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease. Int J Mol Sci 2021;22:6114. [PMID: 34204098 DOI: 10.3390/ijms22116114] [Reference Citation Analysis]
282 Pausch AM, Kammerer S, Weber F, Herr W, Stroszczynski C, Holler E, Edinger M, Wolff D, Weber D, Jung EM, Wertheimer T. Parametric Imaging of Contrast-Enhanced Ultrasound (CEUS) for the Evaluation of Acute Gastrointestinal Graft-Versus-Host Disease. Cells 2021;10:1092. [PMID: 34063640 DOI: 10.3390/cells10051092] [Reference Citation Analysis]
283 Mayor NP, Wang T, Lee SJ, Kuxhausen M, Vierra-Green C, Barker DJ, Auletta J, Bhatt VR, Gadalla SM, Gragert L, Inamoto Y, Morris GP, Paczesny S, Reshef R, Ringdén O, Shaw BE, Shaw P, Spellman SR, Marsh SGE. Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. J Clin Oncol 2021;39:2397-409. [PMID: 33835855 DOI: 10.1200/JCO.20.03643] [Reference Citation Analysis]
284 Wertheimer T, Tugues S. IFN-λ: paving the road toward tissue protection in GVHD. Blood 2021;138:596-7. [PMID: 34436528 DOI: 10.1182/blood.2021012348] [Reference Citation Analysis]
285 Herrera L, Santos S, Vesga MA, Carrascosa T, Garcia-Ruiz JC, Pérez-Martínez A, Juan M, Eguizabal C. The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers. Cancers (Basel) 2021;13:5418. [PMID: 34771581 DOI: 10.3390/cancers13215418] [Reference Citation Analysis]
286 Li M, Soder R, Abhyankar S, Abdelhakim H, Braun MW, Trinidad CV, Pathak HB, Pessetto Z, Deighan C, Ganguly S, Dawn B, McGuirk J, Dunavin N, Godwin AK. WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1. J Extracell Vesicles 2021;10:e12067. [PMID: 33598108 DOI: 10.1002/jev2.12067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
287 Ma T, Chen Y, Li LJ, Zhang LS. Opportunities and Challenges for Gut Microbiota in Acute Leukemia. Front Oncol 2021;11:692951. [PMID: 34307157 DOI: 10.3389/fonc.2021.692951] [Reference Citation Analysis]
288 Harlé G, Kowalski C, Garnier L, Hugues S. Lymph Node Stromal Cells: Mapmakers of T Cell Immunity. Int J Mol Sci 2020;21:E7785. [PMID: 33096748 DOI: 10.3390/ijms21207785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
289 Zaghi E, Calvi M, Di Vito C, Mavilio D. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies. Front Immunol 2019;10:2794. [PMID: 31849972 DOI: 10.3389/fimmu.2019.02794] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
290 Yao WL, Wen Q, Zhao HY, Tang SQ, Zhang YY, Wang Y, Xu LP, Zhang XH, Huang XJ, Kong Y. Different subsets of haematopoietic cells and immune cells in bone marrow between young and older donors. Clin Exp Immunol 2021;203:137-49. [PMID: 33020903 DOI: 10.1111/cei.13531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
291 Karl F, Hudecek M, Berberich-Siebelt F, Mackensen A, Mougiakakos D. T-Cell Metabolism in Graft Versus Host Disease. Front Immunol 2021;12:760008. [PMID: 34777373 DOI: 10.3389/fimmu.2021.760008] [Reference Citation Analysis]
292 Kurtzberg J, Prockop S, Chaudhury S, Horn B, Nemecek E, Prasad V, Satwani P, Teira P, Hayes J, Burke E;  MSB-275 Study Group. Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. Biol Blood Marrow Transplant. 2020;26:855-864. [PMID: 32044400 DOI: 10.1016/j.bbmt.2020.01.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
293 Carpenter RA, Kwak JG, Peyton SR, Lee J. Implantable pre-metastatic niches for the study of the microenvironmental regulation of disseminated human tumour cells. Nat Biomed Eng 2018;2:915-29. [PMID: 30906645 DOI: 10.1038/s41551-018-0307-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
294 Kunadt D, Stölzel F. Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Cancer Manag Res 2021;13:7411-27. [PMID: 34594134 DOI: 10.2147/CMAR.S261721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Di Ianni M, Del Papa B, Baldoni S, Di Tommaso A, Fabi B, Rosati E, Natale A, Santarone S, Olioso P, Papalinetti G, Giancola R, Accorsi P, Di Bartolomeo P, Sportoletti P, Falzetti F. NOTCH and Graft-Versus-Host Disease.Front Immunol. 2018;9:1825. [PMID: 30147692 DOI: 10.3389/fimmu.2018.01825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
296 Toubai T, Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood 2020;136:429-40. [PMID: 32526035 DOI: 10.1182/blood.2019000953] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
297 Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency Diseases: Current Status and Future Perspectives. Front Pediatr 2019;7:295. [PMID: 31440487 DOI: 10.3389/fped.2019.00295] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 19.7] [Reference Citation Analysis]
298 Srinivasan A, Bajana S, Pankow A, Yuen C, Shah RK, Sun XH. Type 2 innate lymphoid cells from Id1 transgenic mice alleviate skin manifestations of graft-versus-host disease. BMC Immunol 2021;22:46. [PMID: 34256699 DOI: 10.1186/s12865-021-00432-w] [Reference Citation Analysis]
299 Zhou X, Jin N, Wang F, Chen B. Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease. Cancer Cell Int 2020;20:114. [PMID: 32280306 DOI: 10.1186/s12935-020-01193-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
300 Fürst D, Neuchel C, Tsamadou C, Schrezenmeier H, Mytilineos J. HLA Matching in Unrelated Stem Cell Transplantation up to Date. Transfus Med Hemother 2019;46:326-36. [PMID: 31832058 DOI: 10.1159/000502263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]